SBIR Phase I: Nematode Intestinal Proteins as Anthelmintic Targets

SBIR 第一阶段：线虫肠道蛋白作为驱虫靶点

• 批准号: 0215151
• 负责人: Michelle Hresko
• 金额: $ 9.3万
• 依托单位: Divergence, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0215151&HistoricalAwards=false
• 关键词: SBIR; Phase; Nematode; Intestinal; Proteins

0215151HreskoThis Small Business Innovation Research Phase I project proposes to identify potential targets for the development of therapeutic agents to treat infections by parasitic nematodes. Nematode infections represent a serious heath concern for both humans and domesticated animals and, as such, represent a significant market for anthelmintic drugs. This project proposes to test a new approach to the discovery of anthelmintic agents. Divergence, LLC has identified a class of essential nematode-specific genes in Caenorhabditis elegans, representing a rich pool of potential targets for the control of human, animal and plant parsitic nematodes. Antibodies will be produced against a subset of proteins that are predicted to be gut-localized. The antibodies will be used to confirm localization of the protein and to challenge cultures of nematodes. Based on "hidden antigen" vaccine theory, it is anticipated that the antibodies against one or more of the gene-products proposed in this project may disrupt or impair the life cycle of the nematode. Completion of this Phase I project will allow a swift transition into the investigation of parasite genes. Expression of parasite genes introduced into C. elegans, which can be grown in large scale, will allow production of protein for the in vitro screening of peptide or small molecule libraries and for potential vaccine antigens.The commercial application of this project is in the area of therapeutics aimed at both human and animal health.

这个小企业创新研究第一阶段项目旨在确定潜在靶点，用于开发治疗寄生虫感染的治疗药物。线虫感染对人类和家畜都是一个严重的健康问题，因此是驱虫药的一个重要市场。这个项目提议测试一种发现驱虫剂的新方法。Divergence， LLC已经在秀丽隐杆线虫中发现了一类必需的线虫特异性基因，代表了控制人类，动物和植物寄生线虫的丰富潜在靶点。抗体将会针对一组被预测为肠道定位的蛋白质产生。这些抗体将用于确认蛋白质的定位，并挑战线虫的培养物。根据“隐藏抗原”疫苗理论，预计该项目提出的针对一种或多种基因产物的抗体可能会破坏或损害线虫的生命周期。第一阶段项目的完成将使寄生虫基因的研究迅速过渡。将寄生虫基因的表达引入秀丽隐杆线虫，可以大规模生长，将允许生产用于体外筛选肽或小分子文库和潜在疫苗抗原的蛋白质。这个项目的商业应用是针对人类和动物健康的治疗领域。